FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy of opioid-free anesthesia in short-term recovery following laparoscopic-assisted colorectal tumor resection: a randomized trial. PMID 40672749 · Front Oncol · 2025 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| In vitro 3D drug sensitivity testing for patient-derived tumor-like cell clusters and whole-exome sequencing to personalize postoperative treatment: A study protocol for a multicenter randomized controlled trial. PMID 40658653 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial. PMID 40644418 · PLoS One · 2025 The study meets most criteria: it is an oncology, human, randomized trial with a drug intervention and reports a time-to-event efficacy endpoint (3-year DFS) with HR. However, the phase is not explicitly stated in the provided metadata as Phase III/IIIb or Phase II/III (only 'randomized controlled trial' is noted). Additionally, the primary endpoint is safety (thrombocytopenia), while the key secondary endpoint is the efficacy endpoint (DFS). To be eligible, the trial must be explicitly Phase III/IIIb or Phase II/III and the time-to-event endpoint must be the primary or key secondary endpoint of a definitive trial. Without explicit phase confirmation, eligibility cannot be established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of aerobic exercise on body composition and exerkines in colorectal cancer survivors. PMID 40642656 · Front Sports Act Living · 2025 The record describes a randomized trial of aerobic exercise in colorectal cancer survivors with immune biomarker endpoints. It is eligible for oncology and human criteria, but it is excluded because it lacks a drug intervention and a time-to-event efficacy endpoint. The study is not a Phase III/IIIb or Phase II/III trial and does not report Kaplan-Meier or HR data for OS/PFS/DFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer-an open-label phase 2 randomized controlled trial. PMID 40636683 · Front Oncol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Electroacupuncture Prevent and Treat Perioperative Cognitive Impairment in Elderly Patients Undergoing Hip Surgery: A Protocol for a Randomized Controlled Trial. PMID 40606589 · J Pain Res · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. PMID 40546817 · Ther Adv Hematol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of Topical Capsaicin for Chemotherapy-Induced Peripheral Neuropathy (CIPN) Prophylaxis in Oxaliplatin-Treated Cancer Patients: A Double-Blind Randomized Clinical Trial. PMID 40519580 · Adv Biomed Res · 2025 The study is a randomized, double-blind, placebo-controlled trial in cancer patients evaluating a drug (capsaicin) for prevention of chemotherapy-induced peripheral neuropathy. The primary efficacy endpoint is neuropathy grade (ordinal) and symptom severity, which is a toxicity/side-effect outcome, not a time-to-event efficacy endpoint such as OS, PFS, DFS, etc. Therefore, it does not meet the requirement for a Kaplan-Meier or time-to-event primary/key secondary endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of Peer Education on Early Breast Cancer Detection, Health Responsibility, Health Beliefs, Knowledge, and Practices Among University Students. PMID 40518814 · Public Health Nurs · 2025 The study is a randomized controlled trial on early breast cancer detection and education, but it lacks a drug intervention, does not specify a Phase III design, and does not report time-to-event efficacy endpoints like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preoperative Radiotherapy Does Not Increase the Risk for Early Complications Following Surgery for Oral Cancer: A Study on Data From the Randomized ARTSCAN 2 Trial. PMID 40515490 · J Otolaryngol Head Neck Surg · 2025 The study is an RCT in oncology, but it lacks a drug-containing intervention (radiotherapy is non-drug) and does not report a primary/key secondary time-to-event efficacy endpoint; therefore, it does not meet all eligibility criteria for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of perioperative ONS combined with intestinal microecology in patients with colorectal cancer: a randomized clinical trial. PMID 40497027 · Front Nutr · 2025 The record is a randomized trial in human oncology patients with a drug-containing intervention (ONS + probiotic) and reports primary results. However, it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as required by the cohort definition. The endpoints are nutritional status, inflammation, and intestinal function recovery. Additionally, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Comparing Liposomal Bupivacaine and Ropivacaine in Serratus Anterior Plane Block for Thoracoscopic Lobectomy: A Randomized Controlled Trial. PMID 40491528 · Drug Des Devel Ther · 2025 The study is a randomized controlled trial in oncology patients, but it lacks a reported phase, its primary endpoint is a pain score (not time-to-event), and the intervention is a local anesthetic for postoperative pain management, not an anticancer drug intervention for efficacy against the malignant neoplasm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Designing a multi-arm, multi-stage platform trial for venous leg ulceration - Venous leg ulcers: management and eradication, the VEIN platform study.: Designing a platform/adaptive trial for venous leg ulcers (VLU) - The VEIN platform. PMID 40487135 · NIHR Open Res · 2025 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Optimizing muscle mass and function in advanced lung cancer patients: randomized, double-blind, placebo-controlled trial protocol using High Eicosapentaenoic acid and PROtein (HEPRO) to modulate epigenetics, reduce toxicity and improve gut microbiota. PMID 40487055 · PeerJ · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Validation and pilot feasibility study of a novel screener to assess diet, lifestyle and mental health in people living with and beyond cancer: Study protocols. PMID 40472046 · PLoS One · 2025 The record is a protocol for a validation and pilot feasibility study, not a formal report of results from a definitive randomized trial. It does not meet the criteria for Phase III/IIIb or Phase II/III, drug intervention, or time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| GPT-4 generates accurate and readable patient education materials aligned with current oncological guidelines: A randomized assessment. PMID 40465696 · PLoS One · 2025 This is a randomized trial assessing AI-generated patient education materials for oncological guidelines. While it involves oncology and human subjects, it is not a drug intervention trial, does not report Phase III/IIIb or Phase II/III results, and lacks a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. The study's primary outcomes are readability, accuracy, completeness, and clarity scores. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models. PMID 40458731 · Front Oncol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Genomewide association analysis on green tea chemoprevention of colorectal adenoma: the importance of SLCO1A2 variants. PMID 40433816 · Pharmacogenomics · 2025 The record is a post-hoc pharmacogenetic analysis of the MIRACLE trial. It does not meet key inclusion criteria: the intervention is a dietary supplement (green tea extract), not a conventional drug; the primary endpoint is adenoma recurrence (binary), not a time-to-event; and the analysis is a subgroup/biomarker study, not the primary efficacy report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison between the safety of the HPV vaccine versus placebo: a systematic review and meta-analysis of randomized clinical trials. PMID 40425051 · J Pediatr (Rio J) · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of 0.5% Timolol Maleate versus 0.05% Clobetasol Propionate in Treating Superficial Infantile Hemangioma: A Pilot Randomized Controlled Trial. PMID 40406337 · J Indian Assoc Pediatr Surg · 2025 The study is a randomized, placebo-controlled trial in oncology (benign vascular tumor/hemangioma), but it is a Phase II (pilot) study, not Phase III/IIIb or Phase II/III. The primary outcomes are descriptive measures (area reduction, visual analog scale scores) at fixed timepoints, not time-to-event endpoints like OS, PFS, or DFS, and no Kaplan-Meier curves or hazard ratios are reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of Helicobacter pylori eradication on remnant stomach neoplasms after curative gastrectomy (HELP-GC): Protocol of a HELP-GC randomized controlled trial. PMID 40388525 · PLoS One · 2025 The record is a protocol for a randomized controlled trial with drug intervention and time-to-event endpoints, but it is not an original formal result report. It lacks Phase III/IIIb or Phase II/III evidence and presents no efficacy data, so it does not meet eligibility criteria for inclusion in the digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations. PMID 40385479 · Front Pharmacol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of behavioral activation in reducing fear of cancer recurrence in non-small cell lung cancer patients: a randomized controlled trial. PMID 40371137 · Am J Cancer Res · 2025 The study is a randomized trial in oncology patients, but it fails three key eligibility criteria: it is not a definitive phase (Phase III/IIIb or II/III), its primary endpoint is not a time-to-event efficacy outcome, and the intervention is non-drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The effects of saffron supplementation on inflammatory factors and clinical outcomes in sepsis patients admitted to the intensive care unit (ICU): Study protocol for a double-blind randomized controlled clinical trial. PMID 40365184 · Avicenna J Phytomed · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Reduced Port Surgery for Colorectal Cancer. PMID 40355129 · Asian J Endosc Surg · 2025 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Personalized targeted glioblastoma therapies by ex vivo drug screening: Study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT). PMID 40351832 · Neurooncol Adv · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges. PMID 40329596 · Technol Cancer Res Treat · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Resistance exercise combined with protein supplementation for skeletal muscle mass in people with pancreatic cancer undergoing neoadjuvant chemotherapy: Study protocol for the REBUILD trial. PMID 40315221 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Influence of polyfunctional Tbet+ T cells on specific clinical events in chronic lymphocytic leukaemia. PMID 40313965 · Front Immunol · 2025 The record describes a secondary/biomarker analysis from a Phase III randomized trial. While the trial itself is oncology, human, randomized, and drug-interventional, this specific publication does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier results or hazard ratios for the compared treatment regimens. It focuses on correlating baseline T-cell phenotypes with clinical events in a subset of patients. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Real-world comparison of flumatinib and nilotinib as first-line therapy for patients with chronic phase chronic myeloid leukemia: a multicenter retrospective study. PMID 40309039 · Ther Adv Med Oncol · 2025 The study is a retrospective real-world comparison, not a randomized Phase III/IIIb or Phase II/III trial. It does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An internet-delivered psychoeducational intervention (Fex-Can 2.0) targeting fertility-related distress and sexual dysfunction in young adults diagnosed with cancer: Study protocol of a randomized controlled trial with an internal pilot phase. PMID 40300010 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Capecitabine metronomic chemotherapy for metastatic colorectal cancer patients reaching NED: A protocol for a prospective, randomized, controlled trial. PMID 40258007 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of theory-based breast self-examination intervention for breast cancer prevention among female college teachers in Pakistan: A cluster randomized controlled trial study protocol. PMID 40245100 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials. PMID 40209685 · Dermatology · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Qizhu Yuling prescription in the prevention of postoperative metastasis and recurrence of esophagus cancer: study protocol for a randomized, double-blind, placebo-controlled, multicenter clinical trial. PMID 40206581 · Front Oncol · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of PD-1/PD-L1 inhibitors combined with tyrosine kinase inhibitors as first-line treatment for hepatocellular carcinoma: a meta-analysis and trial sequential analysis of randomized controlled trials. PMID 40196369 · Front Pharmacol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Sijunzi decoction granules for the treatment of advanced refractory colorectal cancer: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. PMID 40182845 · Front Med (Lausanne) · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The ReDyor study: Effects of prophylactic swallowing exercises on dysphagia and quality of life in patients with head and neck cancer receiving chemoradiation therapy, a randomized clinical trial. PMID 40179796 · Rehabilitacion (Madr) · 2025 The study is a randomized clinical trial in head and neck cancer patients, but it is not Phase III/IIIb or Phase II/III. It does not contain a drug-containing intervention (exercise-based). It does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) or Kaplan-Meier analysis. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Application of the end-of-life demands card game and mindfulness-based cancer recovery program for reducing negative emotion in patients with advanced lung cancer: a randomized controlled trial. PMID 40177032 · Front Psychol · 2025 The study is a randomized trial in advanced lung cancer patients, but it evaluates psychosocial interventions (a card game and mindfulness program), not a drug. The endpoints are psychometric scales (death anxiety, depression, stress), not time-to-event outcomes (e.g., OS, PFS). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Rikkunshito on Chemotherapy-Induced Nausea and Vomiting in Patients With Uterine Corpus or Cervical Cancer Treated With Cisplatin-Based Regimen-Placebo-controlled, Double-Blind, Randomized Confirmatory Study (JORTC-KMP03). PMID 40156342 · Integr Cancer Ther · 2025 The trial is a randomized, placebo-controlled study in oncology patients with a drug intervention (Rikkunshito) and reports original results. However, the primary endpoint is complete response (CINV), a categorical efficacy endpoint, not a time-to-event endpoint (e.g., OS, PFS, DFS, TTP). The study also does not explicitly report being Phase III or a definitive trial, and the abstract does not mention Phase information. Therefore, it fails the required time-to-event efficacy endpoint criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of honey-ginger mouthwash on oral mucositis in patients undergoing chemotherapy. PMID 40134126 · J Immunoassay Immunochem · 2025 The study is a randomized Phase III trial in oncology patients, but the intervention is a honey-ginger mouthwash for prevention of chemotherapy-induced oral mucositis (a supportive care/symptomatic intervention), not a drug-containing anticancer therapy. The primary endpoints are oral mucositis severity scores and pain intensity, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). Therefore, it does not meet the required criteria for inclusion. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Timing of transcutaneous acupoint electrical stimulation for postoperative recovery in geriatric patients with gastrointestinal tumors: study protocol for a randomized controlled trial. PMID 40109717 · Front Med (Lausanne) · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Synthetic Versus Biologic Mesh for Complex Open Ventral Hernia Repair: 3-Year Follow-Up of a Pilot Randomized Controlled Trial. PMID 40071184 · HCA Healthc J Med · 2025 The study is a randomized controlled trial comparing biologic versus synthetic mesh for hernia repair, which is not an oncology study. It does not involve a drug-containing intervention, and the primary endpoint is major complications (infection, recurrence, reoperation, death), not a time-to-event efficacy endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Conservative endometrioma surgery: The combined technique versus CO2-laser vaporization only (BLAST: Belgium LAser STudy): Clinical protocol for a multicenter randomized controlled trial. PMID 40048474 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| An overview of current phase 3 radiopharmaceutical therapy clinical trials. PMID 40041466 · Front Med (Lausanne) · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized clinical trial in cancer patients shows immune metabolic effects exerted by formulated bioactive phenolic diterpenes with potential clinical benefits. PMID 40034703 · Front Immunol · 2025 The study is a randomized controlled trial in cancer patients with a drug-like intervention (bioactive formula). However, it does not meet the core eligibility criteria: the trial phase is not specified as Phase III/IIIb or Phase II/III, and the primary readouts are immune-metabolic and inflammatory biomarkers, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier analysis or hazard ratio. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The effect of intraoperative low-dose ketamine versus dexmedetomidine infusion on postoperative bowel recovery in patients undergoing gastrointestinal malignancy surgeries: Placebo-controlled, randomized trial. PMID 40026739 · J Anaesthesiol Clin Pharmacol · 2025 Study is a randomized trial in oncology patients but does not meet key eligibility criteria: primary endpoint is not a time-to-event oncology efficacy endpoint (OS/PFS/DFS etc.), and the drug interventions are supportive care agents, not oncology drugs. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Herbal Medicine Bojungikki-Tang in Combination with Pembrolizumab versus Pembrolizumab Monotherapy for Stage IV Non-Small Cell Lung Cancer: Study Protocol for a Randomized, Open-Label, Double-Arm, Multicenter Trial. PMID 39985390 · Integr Cancer Ther · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials. PMID 39958346 · Front Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Transcutaneous Electrical Acupoint Stimulation Improves Postoperative Nutrition and Promotes Early Recovery of Gastrointestinal Function in Patients with Colorectal Cancer. PMID 39957303 · Comb Chem High Throughput Screen · 2025 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |